171 related articles for article (PubMed ID: 18523874)
1. Investigation into the role of tumor-associated macrophages in the antitumor activity of Doxil.
Banciu M; Schiffelers RM; Storm G
Pharm Res; 2008 Aug; 25(8):1948-55. PubMed ID: 18523874
[TBL] [Abstract][Full Text] [Related]
2. Antitumor activity of liposomal prednisolone phosphate depends on the presence of functional tumor-associated macrophages in tumor tissue.
Banciu M; Metselaar JM; Schiffelers RM; Storm G
Neoplasia; 2008 Feb; 10(2):108-17. PubMed ID: 18283332
[TBL] [Abstract][Full Text] [Related]
3. Overcoming Intrinsic Doxorubicin Resistance in Melanoma by Anti-Angiogenic and Anti-Metastatic Effects of Liposomal Prednisolone Phosphate on Tumor Microenvironment.
Licarete E; Rauca VF; Luput L; Drotar D; Stejerean I; Patras L; Dume B; Toma VA; Porfire A; Gherman C; Sesarman A; Banciu M
Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32340166
[TBL] [Abstract][Full Text] [Related]
4. Liposomal glucocorticoids as tumor-targeted anti-angiogenic nanomedicine in B16 melanoma-bearing mice.
Banciu M; Metselaar JM; Schiffelers RM; Storm G
J Steroid Biochem Mol Biol; 2008 Jul; 111(1-2):101-10. PubMed ID: 18602825
[TBL] [Abstract][Full Text] [Related]
5. The prednisolone phosphate‑induced suppression of the angiogenic function of tumor‑associated macrophages enhances the antitumor effects of doxorubicin on B16.F10 murine melanoma cells in vitro.
Licarete E; Rauca VF; Luput L; Patras L; Sesarman A; Banciu M
Oncol Rep; 2019 Dec; 42(6):2694-2705. PubMed ID: 31578578
[TBL] [Abstract][Full Text] [Related]
6. Anti-tumor activity of liposomal glucocorticoids: The relevance of liposome-mediated drug delivery, intratumoral localization and systemic activity.
Kluza E; Yeo SY; Schmid S; van der Schaft DW; Boekhoven RW; Schiffelers RM; Storm G; Strijkers GJ; Nicolay K
J Control Release; 2011 Apr; 151(1):10-7. PubMed ID: 21130819
[TBL] [Abstract][Full Text] [Related]
7. Liposomal simvastatin inhibits tumor growth via targeting tumor-associated macrophages-mediated oxidative stress.
Alupei MC; Licarete E; Patras L; Banciu M
Cancer Lett; 2015 Jan; 356(2 Pt B):946-52. PubMed ID: 25444912
[TBL] [Abstract][Full Text] [Related]
8. Antitumor activity and tumor localization of liposomal glucocorticoids in B16 melanoma-bearing mice.
Banciu M; Fens MH; Storm G; Schiffelers RM
J Control Release; 2008 Apr; 127(2):131-6. PubMed ID: 18291548
[TBL] [Abstract][Full Text] [Related]
9. Anti-angiogenic effects of liposomal prednisolone phosphate on B16 melanoma in mice.
Banciu M; Schiffelers RM; Fens MH; Metselaar JM; Storm G
J Control Release; 2006 Jun; 113(1):1-8. PubMed ID: 16707187
[TBL] [Abstract][Full Text] [Related]
10. Targeting of M2 macrophages with IL-13-functionalized liposomal prednisolone inhibits melanoma angiogenesis
Sesarman A; Luput L; Rauca VF; Patras L; Licarete E; Meszaros MS; Dume BR; Negrea G; Toma VA; Muntean D; Porfire A; Banciu M
J Liposome Res; 2024 Feb; ():1-12. PubMed ID: 38379249
[TBL] [Abstract][Full Text] [Related]
11. Remodeling tumor microenvironment by liposomal codelivery of DMXAA and simvastatin inhibits malignant melanoma progression.
Rauca VF; Patras L; Luput L; Licarete E; Toma VA; Porfire A; Mot AC; Rakosy-Tican E; Sesarman A; Banciu M
Sci Rep; 2021 Nov; 11(1):22102. PubMed ID: 34764332
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic targeting of tumor-associated macrophages in pancreatic neuroendocrine tumors.
Krug S; Abbassi R; Griesmann H; Sipos B; Wiese D; Rexin P; Blank A; Perren A; Haybaeck J; Hüttelmaier S; Rinke A; Gress TM; Michl P
Int J Cancer; 2018 Oct; 143(7):1806-1816. PubMed ID: 29696624
[TBL] [Abstract][Full Text] [Related]
13. Anti-angiogenic and anti-inflammatory effects of long-circulating liposomes co-encapsulating curcumin and doxorubicin on C26 murine colon cancer cells.
Sesarman A; Tefas L; Sylvester B; Licarete E; Rauca V; Luput L; Patras L; Banciu M; Porfire A
Pharmacol Rep; 2018 Apr; 70(2):331-339. PubMed ID: 29477042
[TBL] [Abstract][Full Text] [Related]
14. Experimental anticancer therapy with vascular-disruptive peptide and liposome-entrapped chemotherapeutic agent.
Sochanik A; Mitrus I; Smolarczyk R; Cichoń T; Snietura M; Czaja M; Szala S
Arch Immunol Ther Exp (Warsz); 2010 Jun; 58(3):235-45. PubMed ID: 20383751
[TBL] [Abstract][Full Text] [Related]
15. A novel liposomal Clodronate depletes tumor-associated macrophages in primary and metastatic melanoma: Anti-angiogenic and anti-tumor effects.
Piaggio F; Kondylis V; Pastorino F; Di Paolo D; Perri P; Cossu I; Schorn F; Marinaccio C; Murgia D; Daga A; Raggi F; Loi M; Emionite L; Ognio E; Pasparakis M; Ribatti D; Ponzoni M; Brignole C
J Control Release; 2016 Feb; 223():165-177. PubMed ID: 26742942
[No Abstract] [Full Text] [Related]
16. Low-dose tumor necrosis factor-alpha augments antitumor activity of stealth liposomal doxorubicin (DOXIL) in soft tissue sarcoma-bearing rats.
Ten Hagen TL; Van Der Veen AH; Nooijen PT; Van Tiel ST; Seynhaeve AL; Eggermont AM
Int J Cancer; 2000 Sep; 87(6):829-37. PubMed ID: 10956394
[TBL] [Abstract][Full Text] [Related]
17. Liposomal prednisolone phosphate potentiates the antitumor activity of liposomal 5-fluorouracil in C26 murine colon carcinoma in vivo.
Patras L; Sylvester B; Luput L; Sesarman A; Licarete E; Porfire A; Muntean D; Drotar DM; Rusu AD; Nagy AL; Catoi C; Tomuta I; Vlase L; Banciu M; Achim M
Cancer Biol Ther; 2017 Aug; 18(8):616-626. PubMed ID: 28696813
[TBL] [Abstract][Full Text] [Related]
18. Clodronate-liposome-mediated depletion of tumour-associated macrophages: a new and highly effective antiangiogenic therapy approach.
Zeisberger SM; Odermatt B; Marty C; Zehnder-Fjällman AH; Ballmer-Hofer K; Schwendener RA
Br J Cancer; 2006 Aug; 95(3):272-81. PubMed ID: 16832418
[TBL] [Abstract][Full Text] [Related]
19. Anti-tumor efficacy of tumor vasculature-targeted liposomal doxorubicin.
Schiffelers RM; Koning GA; ten Hagen TL; Fens MH; Schraa AJ; Janssen AP; Kok RJ; Molema G; Storm G
J Control Release; 2003 Aug; 91(1-2):115-22. PubMed ID: 12932643
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics, efficacy and toxicity of different pegylated liposomal doxorubicin formulations in preclinical models: is a conventional bioequivalence approach sufficient to ensure therapeutic equivalence of pegylated liposomal doxorubicin products?
Mamidi RN; Weng S; Stellar S; Wang C; Yu N; Huang T; Tonelli AP; Kelley MF; Angiuoli A; Fung MC
Cancer Chemother Pharmacol; 2010 Nov; 66(6):1173-84. PubMed ID: 20661737
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
